• Explore /
  • Poster
  • / Neoadjuvant versus adjuvant treatment: Which one is better for resectable locally advanced esophageal squamous cell carcinoma?

Neoadjuvant versus adjuvant treatment: Which one is better for resectable locally advanced esophageal squamous cell carcinoma?

Abstract Poster

Authors

null

Qixun Chen

Zhejiang Cancer Hospital, Hangzhou, China

Qixun Chen , Yaping Xu , Yuanda Zheng , Xinmin Yu , Qingren Lin , Youhua Jiang , Xinming Zhou , Weimin Mao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

ChiCTR-TRC-12002665

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 4060)

DOI

10.1200/jco.2014.32.15_suppl.4060

Abstract #

4060

Poster Bd #

147

Abstract Disclosures

Similar Posters

First Author: yueyun chen

Poster

2017 Gastrointestinal Cancers Symposium

Converting borderline-resectable, locally-advanced esophageal carcinoma to resectability with neoadjuvant chemoradiotherapy.

Converting borderline-resectable, locally-advanced esophageal carcinoma to resectability with neoadjuvant chemoradiotherapy.

First Author: Zachary D. Horne

First Author: Lei Liu

First Author: Jhe-Cyuan Guo